Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW.
Hørsholm, Denmark, 12 June 2024 - Today is the first day of the subscription period in ExpreS2ion Biotech Holding AB's ("ExpreS2ion" or the "Company") rights issue of shares and warrants of series TO 10 and TO 11 ("Units") (the "Rights Issue"), which was resolved by the Board of Directors on 2 May 2024, and approved by the Annual General Meeting held on 5 June 2024.
Publication of the prospectus
For complete information about the Rights Issue, please refer to the prospectus that has been prepared by the Company and approved by the SFSA. The prospectus is available in Swedish and English on ExpreS2ion's website (https://investor.expres2ionbio.com/) and is also available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/).
The Rights Issue in briefThe subscription price has been set to SEK 1.00 per Unit, corresponding to SEK 1.00 per share. The warrants of series TO 10 and warrants of series TO 11 are issued free of charge. Upon full subscription in the Rights Issue, the Company will receive initial proceeds of approximately SEK 60 million before deduction of transaction costs.
Upon full subscription in the Rights Issue, the net proceeds from the Rights Issue will be used for (i) ES2B-C001 clinical phase initiation and progression, (ii) discovery pipeline and platform development, (iii) early preclinical development of a cytomegalovirus vaccine candidate, (iii) internal costs related to grant-sponsored projects and (iv) working capital including discovery pipeline and platform development.
Existing shareholders in ExpreS2ion as of the record date, 10 June 2024, will receive seven (7) unit rights for each existing share. Six (6) unit rights entitle to subscription of one (1) Unit in the rights issue.
In total, a maximum of 59,972,451 Units can be issued. Each Unit consists of one (1) share, one (1) warrant of series TO 10 and one (1) warrant of series TO 11, which means that a maximum of 59,972,451 shares, 59,972,451 warrants of series TO 10 and 59,972,451 warrants of series TO 11 can be issued.
The subscription period runs from and including 12 June 2024 until and including 27 June 2024.
Warrants of series TO 10 can be exercised for subscription of shares in the Company during the period from and including 20 November 2024 until and including 4 December 2024. Warrants of series TO 11 can be exercised for subscription of shares in the Company during the period from and including 18 September 2025 until and including 2 October 2025.
Timetable for the Rights Issue
Last day of trading in shares 5 June 2024
including right to receive unit
rights
First day of trading in shares 7 June 2024
excluding right to receive unit
rights
Record date for participation in 10 June 2024
the Rights Issue
Trading in unit rights 12 June 2024 - 24 June 2024
Subscription period 12 June 2024 - 27 June 2024
Trading in BTUs (paid subscribed 12 June 2024 until the Rights Issue is
Units) registered with the Swedish Companies
Registration Office
Announcement of outcome in the On or around 1 July 2024
Rights Issue
Advisors
Vator Securities acts as financial advisor and issuing agent to the Company in connection with the Rights Issue. Schjødt is the Company's legal advisor in connection with the Rights Issue.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.